HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.

Abstract
To prevent important infectious diseases such as tuberculosis, malaria and HIV, vaccines inducing greater T cell responses are required. In this study, we investigated whether fusion of the M. tuberculosis antigen 85A to recently described adjuvant IMX313, a hybrid avian C4bp oligomerization domain, could increase T cell responses in pre-clinical vaccine model species. In mice, the fused antigen 85A showed consistent increases in CD4(+) and CD8(+) T cell responses after DNA and MVA vaccination. In rhesus macaques, higher IFN-γ responses were observed in animals vaccinated with MVA-Ag85A IMX313 after both primary and secondary immunizations. In both animal models, fusion to IMX313 induced a quantitative enhancement in the response without altering its quality: multifunctional cytokines were uniformly increased and differentiation into effector and memory T cell subsets was augmented rather than skewed. An extensive in vivo characterization suggests that IMX313 improves the initiation of immune responses as an increase in antigen 85A specific cells was observed as early as day 3 after vaccination. This report demonstrates that antigen multimerization using IMX313 is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability.
AuthorsAlexandra J Spencer, Fergal Hill, Jared D Honeycutt, Matthew G Cottingham, Migena Bregu, Christine S Rollier, Julie Furze, Simon J Draper, Karen C Søgaard, Sarah C Gilbert, David H Wyllie, Adrian V S Hill
JournalPloS one (PLoS One) Vol. 7 Issue 3 Pg. e33555 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22470455 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Antigens, Bacterial
  • Complement C4b-Binding Protein
  • MVA vaccine
  • Recombinant Fusion Proteins
  • Tuberculosis Vaccines
  • Vaccines, DNA
  • Viral Vaccines
  • Interferon-gamma
  • Acyltransferases
  • antigen 85A, Mycobacterium tuberculosis
  • Tissue Plasminogen Activator
Topics
  • Acyltransferases (genetics, immunology)
  • Adjuvants, Immunologic
  • Animals
  • Antigens, Bacterial (genetics, immunology)
  • CD4-Positive T-Lymphocytes (immunology)
  • CD8-Positive T-Lymphocytes (immunology)
  • Complement C4b-Binding Protein (genetics, immunology)
  • Female
  • Humans
  • Interferon-gamma (metabolism)
  • Macaca mulatta
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mycobacterium tuberculosis (immunology, metabolism)
  • Recombinant Fusion Proteins (genetics, immunology)
  • Tissue Plasminogen Activator (genetics)
  • Tuberculosis Vaccines (genetics, immunology)
  • Vaccination
  • Vaccines, DNA (immunology)
  • Viral Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: